36
Kyiv, 2005-10-05 1 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence Study Design and Conduct Presented by John Gordon, Ph.D. Consultant to WHO e-mail: [email protected]

Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Embed Size (px)

Citation preview

Page 1: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 1

TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY,

GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE

Introduction to the Discussion of Bioequivalence Study

Design and Conduct

Presented byJohn Gordon, Ph.D.Consultant to WHO

e-mail: [email protected]

Page 2: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 2

Background:First Product to Market

Innovator’s Product

Quality

Safety and efficacy– Based on extensive clinical trials– Expensive– Time consuming

Page 3: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 3

Background:Other products with same medicinal ingredient

Subsequent-entry products

Generic products

Multisource products

How do these products gain

marketing authorization?

Page 4: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 4

Pharmaceutical equivalence

Same amount of the same active pharmaceutical ingredient– Salts, esters

Same dosage form– Comparable dosage forms– e.g., tablet vs. capsule

Same route of administration

Is pharmaceutical equivalence enough?

Page 5: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 5

Sometimes pharmaceutical equivalence is enough

Aqueous solutions– Intravenous solutions– Intramuscular, subcutaneous– Oral solutions– Otic or ophthalmic solutions– Topical preparations– Solutions for nasal administration

Powders for reconstitution as solution

Gases

Page 6: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 6

Sometimes it is not enough

Pharmaceutical equivalence by itself

does not necessarily imply

therapeutic equivalence

Therapeutic equivalence:– Pharmaceutically equivalent– Same safety and efficacy profiles after

administration of same dose

Page 7: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 7

Pharmaceutical Equivalents

Possible Differences

Drug particle size

Excipients

Manufacturing

Equipment or

Process

Site of manufacture

Test Reference

Could lead to differences in product performance in vivo

Page 8: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 8

Additional data is required

Oral immediate release products with systemic action– Generally required for solid oral

dosage forms• Critical use• Narrow therapeutic range• Bioavailability problems associated with

the active ingredient• Problematic polymorphism, excipient

interaction, or sensitivity to manufacturing processes

Page 9: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 9

Additional data is required

Oral modified release products with systemic action

Fixed dose combination products with systemic action– When at least one component requires study

Non-oral / non-parental products with systemic action

Non-solution products with non-systemic action

Page 10: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 10

Marketing authorization of multisource products

Extensive clinical trials to

demonstrate safety and efficacy– Interchangeability?

Demonstration of equivalence to

reference (comparator) product– Interchangeability– Therapeutic equivalence

Page 11: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 11

Marketing authorization through equivalence

Suitable methods for assessing

equivalence:– Comparative pharmacokinetic studies– Comparative pharmacodynamic

studies– Comparative clinical trials– Comparative in vitro tests

Page 12: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 12

Comparative Pharmacokinetic Studies

In vivo measurement of active

ingredient

“Some” relationship between

concentration and safety/efficacy

Product performance is the key

Comparative bioavailability

Page 13: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 13

Bioavailability

The rate and extent to which a substance or

its active moiety is delivered from a

pharmaceutical form and becomes available

in the general circulation.”

Reference:

intravenous administration = 100% bioavailability

Page 14: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 14

Important Pharmacokinetic Parameters

AUC: area under the concentration-time curve measure of the extent of bioavailability

Cmax: the observed maximum concentration

of drug measure of both the rate of absorption and the extent of bioavailability

tmax: the time after administration of drug at

which Cmax is observed measure of the

rate of absorption

Page 15: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 15

Plasma concentration time profile

Cmax

Tmax

AUC

time

concentration

Page 16: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 16

Bioequivalence

Two products are bioequivalent if

they are pharmaceutically equivalent

bioavailabilities (both rate and extent) after

administration in the same molar dose are

similar to such a degree that their effects

can be expected to be essentially the same

Page 17: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 17

Therapeutic Equivalence

Therapeutic equivalence:– Pharmaceutically equivalent– Same safety and efficacy profiles after

administration of same dose: bioequivalent

Interchangeability

Page 18: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 18

Comparative Pharmacodynamic Studies

Not recommended when:– active ingredient is absorbed into the

systemic circulation– pharmacokinetic study can be

conducted

Local action / no systemic absorption

Page 19: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 19

Comparative Clinical Studies

Pharmacokinetic profile not possible

Lack of suitable pharmacodynamic

endpoint

Typically insensitive

Page 20: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 20

Comparative in vitro Studies

May be suitable in lieu of in vivo

studies under certain circumstances

Requirements for waiver to be

discussed

Page 21: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 21

When are bioequivalence studies employed?

Multisource product vs. Innovative product

Pre-approval changes – Bridging studies

Post-approval changes

Additional strengths of existing product

Page 22: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 22

Bioequivalence Studies:Basic Design Considerations

Minimize variability not attributable to

formulations

Minimize bias

REMEMBER: goal is to compare

performance of the two products

Page 23: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 23

“Gold Standard” Study Design

Single-dose, two-period, crossover

Healthy volunteers

Subjects receive each formulation

once

Adequate washout

Page 24: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 24

Multiple-dose Studies

More relevant clinically?

Less sensitive to formulation

differences

Page 25: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 25

Multiple-dose Studies may be employed when:

Drug is too potent/toxic for

administration in healthy volunteers– Patients / no interruption of therapy

Extended/modified release products– Accumulation using recommended

dosing interval– In addition to single-dose studies

Page 26: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 26

Multiple-dose Studies may be employed when:

Non-linear pharmacokinetics at

steady-state (e.g., saturable

metabolism)

Assay not sufficiently sensitive for

single-dose study

Page 27: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 27

Crossover vs. Parallel Designs

Crossover design preferred– Intra-subject comparison– Lower variability– Generally fewer subjects required

Parallel design may be useful– Drug with very long half-life– Crossover design not practical

Page 28: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 28

Parallel Design Considerations

Ensure adequate number of subjects

Adequate sample collection – Completion of Gastrointestinal

transit / absorption process– 72 hours normally sufficient

Page 29: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 29

Fasted vs. Fed Designs

Fasted study design preferred– Minimize variability not attributable to

formulation– Better able to detect formulation

differences

Page 30: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 30

Fed Study Designs may be employed when:

Significant gastrointestinal (GI)

disturbance caused by fasted

administration

Product labeling restricts

administration to fed state

Page 31: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 31

Fed Study Design Considerations

Fed conditions depend on local diet

and customs

Dependent on reason for fed design– Avoiding GI disturbance

• Minimal meal to minimize impact– Required due to drug substance /

dosage form• Modified-release products

Page 32: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 32

Fed Study Design Considerations cont.

– Required due to drug substance / dosage form

• Complicated pharmacokinetics• Known effect of food on drug substance

Fed conditions designed to promote

maximal perturbation– High fat– High Calorie– Warm

Page 33: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 33

Replicate vs. non-replicate designs

Standard approach– Non-replicated– Single administration of each product– Average bioequivalence

Page 34: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 34

Replicate Designs

Typically four-period design– Each product administered twice

Intra-subject variability

Subject X formulation interaction

Different approaches possible– Average bioequivalence– Individual bioequivalence

Page 35: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 35

Replicate Designs

Advantages– More information available– Different approaches to assessment

possible

Disadvantages– Bigger commitment for volunteers– More administrations to healthy

volunteers– More expensive to conduct

Page 36: Kyiv, 2005-10-051 TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence

Kyiv, 2005-10-05 36

Discussion

Questions

Comments

Opinions